Explore Arcturus Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for ARCT. Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer ...

HC Wainwright reiterated a “buy” rating and set a $63.00 target price on shares of Arcturus Therapeutics in a research note on Friday, February 14th. BTIG Research initiated coverage on shares ...

This page features the latest Arcturus Therapeutics Holdings Inc share stories and breaking news. Assess the latest information about the Arcturus Therapeutics Holdings Inc stock. Our team of expert ...

The European Commission (EC) has approved CSL and Arcturus Therapeutics’ COVID-19 vaccine Kostaive (ARCT-154) for use in individuals aged 18 years and older. The decision follows a recent ...

“KOSTAIVE and sa-mRNA technology signify a major advancement in vaccine innovation, providing the potential for broader and more enduring protection,” said Joseph Payne, CEO of Arcturus. “This ...

and SAN DIEGO, Feb. 14, 2025 /PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the European ...

SAN DIEGO - Arcturus Therapeutics (NASDAQ:ARCT) Holdings Inc. (NASDAQ: ARCT), a company specializing in mRNA medicines for infectious diseases and rare disorders, has appointed Dr. Moncef Slaoui as ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...